Biocon Features in Asia IP Elite 2016 List

The only Pharmaceutical Company from India to be recognized for IP-led Value Creation

Bengaluru, Karnataka, India, December 09, 2016

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, has been recognized for its world class Intellectual Property (IP) management and IP value creation in the Asia region by IP Business Congress Asia (IPBC Asia) and has made its debut on the prestigious Asia IP Elite 2016 list. Biocon is the only pharmaceutical company out of the six Indian companies included in this exclusive group.

The prestigious list comprises 62 most influential companies from nine countries in Asia, such as Alibaba, Baidu, Canon, Fujifilm, Samsung Electronics, LG Electronics, Acer and ASUStek, which have all been recognized for excellence in IP and best in-class in-house IP functions.

The companies selected as the Asia IP Elite were honoured at the latest edition of the IP Business Congress Asia, held in Shanghai, which is the most important event addressing IP value creation to be held in Asia. The Congress was attended by over 400 senior IP decision makers from major IP owning companies.

Biocon has over the years built its credibility as an innovation-led enterprise through an excellent track record of intellectual property value creation in discovery, research and development. The Company has an IP portfolio of 1250 patent applications out of which 990 are granted patents and 820 trademark applications consisting of 460 registered trademarks.

Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: “We are pleased to be the only pharma company from India to be recognized for our excellence in IP and included in the prestigious Asia IP Elite list 2016. In our pursuit of innovation, we have consistently created intellectual wealth through our incisive IP strategy which has not only given us a competitive advantage but also created exponential and enduring value for Biocon’s stakeholders.”

IPBC Asia is an event that addresses IP value creation and is hosted by Intellectual Asset Management, the publishers of the world’s leading IP magazine IAM. The IPBC Asia program is focused on how rights owners can strategically use intellectual property to secure greater operational flexibility, drive revenues, enhance bottom-line returns, increase shareholder value and gain greater leverage in the financial markets.

Through an extensive research process incorporating both quantitative and qualitative angles the IAM editorial team has identified 62 organisations across Asia to be inducted into the 2016 Asia IP Elite List. Each Asia IP Elite member demonstrates excellence in IP value creation and adheres to the following criteria:

• Placing IP strategy at the centre of its business.
• Obtaining demonstrable, significant and on-going value from IP as a direct result of the strategies it employs.
• Ensuring that there is a direct line from its IP function to the senior management of the overall business.
• Possessing a senior management that understands the operational and strategic importance of IP.
• Constantly reappraising and improving its IP strategy in order to take advantage of market developments.
  

About Biocon
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from ‘Lab to Market’. Some of its key brands are INSUGEN^®(rh-insulin), BASALOG^® (Glargine), CANMAb^™ (Trastuzumab), BIOMAb-EGFR^™ (Nimotuzumab) and ALZUMAb^™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog. For more information, Visit: www.biocon.com

About IAM
IAM is universally acknowledged as the world’s leading IP business information provider. IAM was launched in July 2003 to address the need for organisations to maximise the value of their intellectual property and other intangibles, and to examine the strategies that they can put in place to do this. IAM is unique because it treats intellectual property as a business asset and tool, rather than simply as a legal right. With this unequalled boardroom, IAM has firmly established itself as the only IP publication that many senior corporate executives read regularly.